Development of resistance to amphotericin B in Candida lusitaniae infecting a human

Antimicrob Agents Chemother. 1979 Aug;16(2):123-6. doi: 10.1128/AAC.16.2.123.

Abstract

Candida lusitaniae associated with infection in a patient with acute myelogenous leukemia developed resistance to amphotericin B during systemic treatment of the patient. The organism, when isolated initially, was inhibited by 0.31 mug of amphotericin B per ml in yeast nitrogen base agar, but when isolated (20 days later) just antemortem and postmortem, required 100 and 50 mug/ml, respectively, for complete inhibition at 48 h.

Publication types

  • Case Reports

MeSH terms

  • Amphotericin B / therapeutic use*
  • Candidiasis / complications
  • Candidiasis / drug therapy*
  • Drug Resistance, Microbial
  • Humans
  • Leukemia, Myeloid, Acute / complications
  • Male
  • Middle Aged

Substances

  • Amphotericin B